Menu
GWAS Study

Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.

Ta M, Blauwendraat C, Antar T et al.

37539664 PubMed ID
GWAS Study Type
5411 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

TM
Ta M
BC
Blauwendraat C
AT
Antar T
LH
Leonard HL
SA
Singleton AB
NM
Nalls MA
IH
Iwaki H
Chapter II

Abstract

Summary of the research findings

Amyloid-β, phosphorylated tau (p-tau), and total tau (t-tau) in cerebrospinal fluid are established biomarkers for Alzheimer's disease (AD). In other neurodegenerative diseases, such as Parkinson's disease (PD), these biomarkers have also been found to be altered, and the molecular mechanisms responsible for these alterations are still under investigation. Moreover, the interplay between these mechanisms and the diverse underlying disease states remains to be elucidated.

5,411 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

5411
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.